Tisento-Logo-HRZ-RGB.png
First Participant Dosed in Tisento Therapeutics’ Global Phase 2b PRIZM Study Evaluating Zagociguat for the Treatment of MELAS
January 27, 2025 07:00 ET | Tisento Therapeutics Inc
The first patient has been dosed in Tisento's global Phase 2b PRIZM study investigating zagociguat in MELAS.
Bridging Health Equi
Bridging Health Equity Gaps: Creyos Launches an Even More Accessible Patient Experience
November 05, 2024 08:00 ET | Creyos
Toronto, Canada, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Creyos, a leader in cognitive and behavioral health assessment, has announced significant enhancements to its online platform to improve...
download.png
Green Bioactives Reports Remarkable Cognitive Benefits of its Newly Launched Memory-boosting Nutraceutical Product, GBL-Memory¹
May 30, 2024 03:00 ET | Green Bioactives Limited
A clinical study, published in the journal Food Science and Nutrition, showed that GBL-Memory1, a unique combination of L-theanine and Fructooligosaccharides, can improve memory by up to 10.1%...
Blue California successfully completes groundbreaking human clinical trial of ergothioneine.
Blue California completes groundbreaking human clinical trial on ErgoActive® ergothioneine intervention for cognitive function, memory, and sleep
February 05, 2024 04:00 ET | Blue California Ingredients
Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Blue California, an industry leader in science-driven ingredient development, announced the successful completion of a...
Axsome Logo.png
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
December 07, 2022 07:00 ET | Axsome Therapeutics, Inc.
Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12 months Improvement in disability, measured by the SDS, starting...
Healthy Extracts Introduces Breakthrough Nutraceutical Formulation, Ultimate Brain Nutrients ACTIVATE™, Clinically Proven to Enhance Key Brain Activity by 46%
July 08, 2021 08:31 ET | Healthy Extracts Inc
LAS VEGAS, July 08, 2021 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading developer and manufacturer of science-forward, clinically proven, plant-based products for heart and brain...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy
December 03, 2019 06:00 ET | Axsome Therapeutics, Inc.
Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p<0.001 on primary endpoint) Reduced excessive daytime sleepiness compared to placebo (p=0.003 on ESS;...
EC logo 400x400.jpg
Elemental Cognition Adds Three Notable Advisors
October 10, 2019 07:00 ET | Elemental Cognition
WILTON, Conn., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Elemental Cognition, the artificial intelligence company founded and led by Dr. David Ferrucci, creator of IBM’s Watson, and funded to date by global...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Presents Data Demonstrating Positive Activity of NYX-458 on Cognitive Performance and Biomarkers in a Preclinical Model of Head Injury
August 21, 2019 08:33 ET | Aptinyx Inc.
EVANSTON, Ill., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Reports Second Quarter 2019 Financial Results and Highlights
August 12, 2019 06:33 ET | Aptinyx Inc.
Reported that NYX-2925 met primary and secondary endpoints in Phase 2 fibromyalgia study On track to initiate three additional Phase 2 studies in 2H 2019 across pipeline of CNS product candidates ...